Rheumatic Disease and Cardiovascular Risk: Why Inflammation Matters Beyond the Joints
Rheumatic disease is often discussed in terms of joints, muscles, pain and stiffness. Yet some inflammatory rheumatic conditions can also influence health well beyond the musculoskeletal system.
One important example is cardiovascular health.
People with rheumatoid arthritis, lupus, psoriatic arthritis and some other inflammatory diseases may have a higher risk of heart attack, stroke or other vascular problems than people without these conditions. That does not mean cardiovascular disease is inevitable. It means that inflammation, disease activity, medication exposure and conventional cardiovascular risk factors should be considered together.
The most useful approach is neither to alarm patients nor to focus only on their joints. It is to control inflammatory disease effectively while also paying appropriate attention to blood pressure, cholesterol, diabetes, smoking, physical activity and other aspects of long-term health.
What do we mean by cardiovascular risk?
Cardiovascular disease includes conditions affecting the heart and blood vessels. These include coronary artery disease, heart attack, stroke and peripheral arterial disease.
Cardiovascular risk is not the same as having cardiovascular disease. It describes the likelihood of developing one of these problems over time.
Age, family history, smoking, high blood pressure, diabetes and abnormal cholesterol levels are familiar risk factors. In some inflammatory rheumatic diseases, persistent inflammation may add to this background risk.
The effect is not identical in every condition or every patient. Someone with well-controlled inflammatory arthritis, normal blood pressure, no diabetes and no smoking history has a different risk profile from someone with active disease, prolonged steroid exposure and several conventional cardiovascular risk factors.
This is why individual assessment matters more than broad statements about risk.
How can inflammation affect the blood vessels?
Inflammation is part of the body’s normal response to infection or injury. In autoimmune inflammatory disease, however, immune activity may remain switched on inappropriately.
Persistent inflammation can affect the lining and function of blood vessels and may contribute to the development and instability of atherosclerotic plaque—the fatty and inflammatory material that can accumulate within arteries.
This does not mean that a raised CRP on one occasion directly causes a heart attack. Cardiovascular risk reflects exposure over time. The duration and severity of inflammation, conventional risk factors, physical health and treatment all contribute.
It is also important to distinguish genuine immune-mediated inflammation from the broader way in which the word “inflammation” is sometimes used to describe any pain, fatigue or sense of poor health. These are not necessarily the same. This distinction is explored in Inflammation: What Rheumatologists Mean.
Rheumatoid arthritis and inflammatory joint disease
Rheumatoid arthritis is one of the clearest examples of a rheumatic disease associated with increased cardiovascular risk.
The explanation is not simply that people with rheumatoid arthritis have more conventional risk factors. Persistent systemic inflammation appears to contribute independently, particularly when disease activity remains high over time.
Pain, stiffness and disability may also make physical activity more difficult. Steroid exposure, weight change, poor sleep and associated depression can add further complexity. Some patients have high blood pressure, diabetes or abnormal cholesterol levels that have not received much attention because the immediate focus has understandably been on controlling their joints.
Psoriatic arthritis and axial spondyloarthritis can raise similar considerations. Psoriasis is itself associated with metabolic and cardiovascular risk factors, while pain and reduced mobility may affect activity and weight. The precise level of cardiovascular risk varies, but long-term care should look beyond symptom control alone.
Treating inflammatory disease effectively is therefore important not only for pain and joint protection, but for the wider health context in which the disease occurs.
Lupus and cardiovascular health
Systemic lupus erythematosus can influence cardiovascular risk through several different pathways.
Persistent inflammation may contribute to accelerated atherosclerosis. Kidney involvement can lead to high blood pressure and other metabolic changes. Steroid exposure may affect blood pressure, glucose, weight and cholesterol. Some patients also have conventional risk factors unrelated to lupus.
Age is important, but younger age does not remove the issue completely. A younger woman with lupus may have a low calculated cardiovascular risk because standard tools are strongly influenced by age, even though lupus-related factors may still deserve attention.
This does not mean every person with lupus requires a statin or extensive cardiac investigation. It means that blood pressure, cholesterol, kidney health, smoking and disease activity should not be overlooked simply because the patient is young.
Antiphospholipid syndrome is a different vascular problem
Antiphospholipid syndrome—or APS—deserves separate consideration.
APS is associated with an increased tendency to form blood clots. It may cause venous thrombosis, pulmonary embolism, stroke or pregnancy complications. This is not identical to the gradual development of atherosclerotic cardiovascular disease, although an individual may have risk factors for both.
A positive antiphospholipid antibody on its own does not necessarily establish APS. The diagnosis depends on the antibody pattern, persistence of the results and the relevant clinical history.
For patients with established APS, management may include antiplatelet or anticoagulant treatment depending on the circumstances. Conventional cardiovascular factors such as smoking and high blood pressure remain important because they may add to the overall vascular risk.
Gout and cardiovascular risk
Gout is not an autoimmune disease, but it is an inflammatory arthritis closely associated with cardiovascular and metabolic health.
People with gout frequently also have high blood pressure, kidney disease, diabetes, excess weight, abnormal lipids or established cardiovascular disease. High uric acid is part of this wider picture, although the relationships are complex and should not be reduced to the idea that uric acid alone causes cardiovascular disease.
A gout consultation should therefore address more than the painful joint. Recurrent attacks may provide an opportunity to review kidney function, blood pressure, weight, alcohol intake, diabetes risk and cardiovascular health while also establishing an effective urate-lowering plan.
This is discussed in more detail in Gout and Cardiovascular Risk: Why Recurrent Gout Should Be Taken Seriously.
Traditional risk factors still matter
It can be tempting to focus on inflammation as though it replaces the usual cardiovascular risk factors. It does not.
Smoking, high blood pressure, diabetes, cholesterol, family history, age and physical inactivity remain central. In many patients, these factors have a greater influence on absolute cardiovascular risk than the rheumatic diagnosis itself.
The difference is that inflammatory disease may interact with them. Smoking may increase cardiovascular risk while also worsening the outlook of some inflammatory diseases. Reduced mobility can make exercise and weight management more difficult. Steroids may affect blood pressure, glucose and body composition. Menopause may alter cholesterol, blood pressure, body composition and vascular risk during the same years in which a woman is managing a rheumatic condition.
Good care should therefore avoid treating “inflammatory risk” and “ordinary risk” as separate problems. They belong to the same patient.
Why risk calculators do not always tell the whole story
Cardiovascular risk calculators are useful. In the UK, tools such as QRISK are commonly used to estimate the likelihood of a heart attack or stroke over the following ten years.
These estimates help guide decisions about interventions such as statin treatment. However, no calculator captures every clinical detail perfectly.
Age has a strong influence on estimated ten-year risk. A younger person with lupus or longstanding inflammatory arthritis may therefore receive a relatively low score despite having disease-related factors that deserve attention. Conversely, an older person may have a high calculated risk predominantly because of age, even if their inflammatory disease is well controlled.
A risk score should inform clinical judgement rather than replace it. The result needs to be interpreted alongside disease activity, kidney function, medication exposure, family history and any previous cardiovascular events.
Does controlling rheumatic disease reduce cardiovascular risk?
Effective control of inflammatory disease is an important part of the overall strategy.
Reducing persistent inflammation is likely to be better for vascular health than leaving active disease untreated. It also improves mobility, function and the ability to exercise. However, disease control should not be presented as a substitute for managing blood pressure, diabetes or cholesterol.
No patient should assume that taking a DMARD or biologic automatically protects them from cardiovascular disease. Equally, concern about cardiovascular risk should not lead someone to stop effective rheumatology treatment without discussing the balance of benefits and risks.
Treatment decisions are individual. They depend on the rheumatic diagnosis, previous response, infection risk, cardiovascular history and the known safety profile of each medicine.
Steroids: valuable treatment with important trade-offs
Corticosteroids can be essential in rheumatology. They may rapidly control inflammation and can be organ-saving or sight-saving in conditions such as vasculitis and giant cell arteritis.
The concern arises with cumulative exposure, particularly at higher doses or over prolonged periods. Steroids can contribute to raised blood pressure, elevated glucose, weight gain and changes in cholesterol and body composition. They also affect bone health and infection risk.
The goal is not to portray steroids as inherently harmful. It is to use the lowest effective dose for the shortest appropriate period while introducing steroid-sparing treatment when the clinical situation allows.
In some diseases, ongoing low-dose steroid treatment may still represent the best balance. That decision should be made in the context of the whole patient rather than through a rigid rule.
NSAIDs, pain control and cardiovascular considerations
Non-steroidal anti-inflammatory drugs—or NSAIDs—can be very useful for inflammatory and mechanical musculoskeletal pain.
However, they may raise blood pressure, cause fluid retention and affect kidney function. Some NSAIDs also carry greater cardiovascular risk than others, particularly at higher doses or with prolonged use.
This does not mean that everyone with cardiovascular risk must avoid NSAIDs completely. Short-term treatment may still be reasonable for many patients. The decision depends on the indication, dose, duration, kidney function, blood pressure, gastrointestinal risk and any history of heart disease or stroke.
Regularly taking an over-the-counter NSAID without reviewing these factors is less sensible than using it within a clear treatment plan.
Modern targeted treatments and cardiovascular risk
Biologic and targeted treatments have transformed the management of inflammatory rheumatic disease. By controlling inflammation, they may improve several aspects of long-term health. However, different treatments have different safety considerations.
For example, current safety advice for JAK inhibitors requires particular care in patients who are older, smoke or have smoked for a long time, or have cardiovascular, thrombotic or cancer risk factors. This does not mean these medicines are inappropriate for everyone. It means that their benefits and alternatives must be considered individually.
The wider principle applies across rheumatology: treatment choice should take account of the person’s complete medical profile, not just the severity of their joint symptoms.
What should a practical cardiovascular review include?
A useful review begins with the basics.
Blood pressure should be measured properly rather than assumed to be normal. Lipids and diabetes risk should be assessed at appropriate intervals. Smoking should be discussed directly but without judgement. Kidney function, weight, family history, previous vascular events and current medication all contribute to the picture.
The frequency of review will vary. A young patient with stable disease and no additional risk factors will not require the same approach as someone with longstanding active inflammation, diabetes, kidney disease or previous cardiovascular disease.
It is also worth asking who is coordinating this aspect of care. Rheumatologists are responsible for recognising that cardiovascular risk matters, but risk-factor treatment will often be shared with primary care, cardiology or other specialists.
The objective is coordinated prevention, not duplication.
Physical activity when joints are painful
Exercise is central to cardiovascular health, but generic advice to “exercise more” can feel unrealistic to someone living with pain, fatigue or reduced mobility.
The most useful activity is one that is safe, sustainable and matched to current function. Walking, cycling, swimming, resistance exercise and supervised rehabilitation can all be appropriate, depending on the person and the disease.
During an inflammatory flare, activity may need to be modified. Persistent inactivity, however, can lead to deconditioning, reduced muscle strength and greater cardiovascular risk. Effective disease treatment and appropriate physiotherapy can help make movement possible again.
The aim is not athletic performance. It is to reduce prolonged inactivity and preserve cardiovascular fitness, strength and independence.
Diet, weight and smoking
There is no single “cardiovascular rheumatology diet.”
A Mediterranean-style dietary pattern is a sensible general model because it supports cardiovascular health and is sustainable for many people. That means an emphasis on vegetables, fruit, legumes, whole grains, nuts, olive oil and fish rather than restrictive detoxes or lists of supposedly inflammatory foods.
Where excess weight is relevant, gradual weight reduction may improve blood pressure, diabetes risk, mobility and overall health. However, weight should not become a simplistic explanation for every symptom or a substitute for treating active inflammatory disease.
Smoking cessation is particularly important. Smoking affects vascular risk and is associated with worse outcomes in some rheumatic diseases. Supportive, evidence-based help is more useful than simply telling someone to stop.
More detail is available in Diet and Rheumatic Disease: Where It Helps—and Where Claims Go Too Far.
Menopause and changing cardiovascular risk
Menopause deserves specific consideration because many women with rheumatic disease reach menopause while also managing inflammation, medication and changes in physical activity.
Falling oestrogen levels may be accompanied by changes in cholesterol, blood pressure, body composition and bone health. Sleep disruption, joint symptoms and fatigue may make exercise harder. Steroid exposure or inflammatory disease may add further complexity.
This is another situation in which symptoms and risks should not be placed into separate boxes. Menopause-related change and rheumatic disease can coexist, and both may need attention.
See Menopause and Rheumatic Disease for a fuller discussion.
Symptoms that require urgent assessment
Cardiovascular prevention is usually a long-term process, but some symptoms require immediate action.
New central chest pressure or tightness, particularly if associated with sweating, nausea, breathlessness or pain spreading to the arm, back, neck or jaw, may indicate a heart attack. Sudden weakness, facial asymmetry, altered speech or loss of vision may indicate a stroke. Sudden unexplained breathlessness, chest pain on breathing or one-sided leg swelling may suggest a blood clot.
These symptoms should not wait for a routine rheumatology or GP appointment. Urgent emergency assessment is required.
The bottom line
Inflammatory rheumatic disease can matter beyond the joints.
Persistent inflammation may contribute to cardiovascular risk, but it is only one part of the picture. Blood pressure, cholesterol, diabetes, smoking, physical activity, kidney health, medication exposure and family history remain fundamental.
The right response is not alarm and it is not excessive cardiac testing. It is proportionate prevention: controlling inflammatory disease effectively, identifying conventional risk factors, reviewing treatment in the context of the whole patient and ensuring that cardiovascular health is not forgotten.
For many people, the most valuable change is not dramatic. It may be checking blood pressure properly, treating cholesterol when appropriate, reducing steroid exposure, stopping smoking, becoming more active or bringing persistent inflammation under better control.
Good rheumatology care protects more than joints. It should support long-term health as a whole.
This article provides general information and does not constitute individual medical advice. Anyone concerned about their cardiovascular or rheumatological health should seek assessment from an appropriate healthcare professional. Symptoms suggesting a heart attack, stroke or blood clot require urgent medical attention.